Records containing: Rifampicin Resistant Tuberculosis

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-03-23
Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis
CLINICAL_TRIALS study record update · 2025-12-08
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort
CLINICAL_TRIALS study record update · 2025-04-06
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
CLINICAL_TRIALS study record update · 2025-02-18
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care: The XPEL-TB Trial
CLINICAL_TRIALS study record update · 2024-08-28
An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current South African Standard of Care (Control Strategy) for 9 Months for the Treatment of Rifampicin Resistant Tuberculosis (RR-TB)
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2021-10-15
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
CLINICAL_TRIALS study record update · 2017-02-14
Multi-center Study to Assess the Non-inferiority of YD REBA MTB-MDR® and Hain GenoType® MTBDRplus V2 Line Probe Assays Compared to Hain GenoType® MTBDRplus V1